The Indian generic company Ranbaxi is one of the largest manufacturers of pharmaceuticals. It is a recognized international company, the production of which is based on its own scientific developments. The company produces a fairly wide assortment list of high quality medicines and affordable prices for a wide range of consumers.
Ranbaxi drugs are popular with patients all over the world. The company's products were presented on the pharmacological market of Russia in the early nineties of the last century. The Ketanov and Fenyuls tablets, as well as Zanopin and Tsifran, manufactured by Ranbaxi, are widely known to many doctors and pharmacists. In the pharmacy network, their implementation is done without a prescription and occupies one of the leading places among antibiotics and analgesics.
The company produces a fairly large assortment of modern medicines used in the field of gastroenterology, in the treatment of heart and vascular diseases, as well as during a course of therapy that restores metabolic processes in the patient's body. The Tsifran OD, Klabaks OD, and Zanocin OD tablets, which belong to the antibiotic group, introduced by Ranbaxi in the year 2000, are the result of a unique scientific development. It allowed to reduce the rate of release in the body of the active substance. Currently, the use of the drug "Tsifran OD" is widely practiced to get rid of many existing types of infections.
Innovative kits “Pilobact” and “Pilobact AM” are also presented on the Russian drug market. Their use is intended for the eradication of H-pilori and has high therapeutic efficacy.
Ofloxacin tablets are manufactured by Ranbaxi for the treatment of a drug-resistant form of tuberculosis . To get rid of this pathology, the company also produces Levofloxacin infusion.
The company occupies one of the leading places as a manufacturer of fluoroquinolone antibiotics.
Starting from two thousand of the first year, Ranbaxi offers AIDS pills, which belong to the group of antiretroviral drugs. These drugs have received WHO approval for mass release. These high-quality and affordable drugs will be especially in demand in such underdeveloped and developing countries as Africa and Asia, Latin America.
The company supports any program aimed at combating HIV infection by providing the necessary medicines. The laboratories, production facilities, as well as research and development of the Ranbaxi company correspond to the modern levels of the GMP standard, from which drugs are introduced into the market in a fairly short time. This includes both branded and specialized generic medicines.
Generic drugs Ranbaxi, the instructions for use which indicate their high therapeutic effect, are constantly updated with new lists. The company currently serves patients from one hundred and twenty-five countries. The company is constantly expanding the list of subsidiaries of international type, joint organizations and associations.
The direct activity of the company is carried out in forty-six countries, and its production is located in seven states. Occupying a strong position in world markets, the company represents a large number of innovative drugs. This allows you to increase the availability of high quality and affordable products.